Alnylam Pharmaceuticals Inc (ALNY)vsPluri Inc. (PLUR)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
PLUR
Pluri Inc.
$3.05
-0.33%
HEALTHCARE · Cap: $34.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 277889% more annual revenue ($3.71B vs $1.34M). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
PLUR
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for PLUR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
3.1% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : PLUR
PLUR has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : PLUR
The primary concerns for PLUR are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while PLUR is a value play — different risk/reward profiles.
PLUR carries more volatility with a beta of 0.57 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 24/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Pluri Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Pluri Inc. is a cutting-edge biotechnology company specializing in regenerative medicine and immunotherapy, with a strong emphasis on developing innovative cell-based therapies. Utilizing its proprietary technology platform, Pluri aims to tackle significant unmet medical needs in oncology and degenerative diseases. The company boasts a robust pipeline and strategic partnerships that position it to improve patient outcomes and capitalize on growth opportunities within the dynamic healthcare landscape. By focusing on the transformative potential of human cells, Pluri is establishing itself as a key player in the biotechnology industry, committed to advancing novel therapeutic solutions.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?